Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

4500 IBD patients enrolled in quest for early warning biomarkers

NCT ID NCT07172945

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This observational study will follow 4500 adults with Crohn's disease or ulcerative colitis to identify biological markers—such as gut bacteria patterns—that predict disease progression and complications. Researchers will collect blood, stool, saliva, and tissue samples during routine care. The goal is to better understand why IBD behaves differently in each person and to improve treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify early warning signs of disease worsening or treatment failure, helping doctors personalize care for IBD patients.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and findings may take years to confirm or apply in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 4,500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Nov 2040

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all patients and control subjects * Person able to give free and informed consent. * Age ≥ 18 years. * Beneficiary of a social protection scheme or entitled person (excluding AME). * Consultation in the Gastroenterology and Nutrition Department of Saint-Antoine Hospital Patients with IBD : \- Patients with Crohn's disease or haemorrhagic rectocolitis with a diagnosis established or confirmed in the Gastroenterology and Nutrition Department at Saint-Antoine Hospital. Microbiota control' subjects: \- Healthy subjects seen in consultation as a preventive measure or as part of stool donations for FMT. Endoscopy control' subjects: \- Subjects with a medical indication for digestive endoscopy with biopsies: * For upper endoscopy: moderate upper digestive symptoms such as epigastralgia or pyrosis * For colonoscopy: moderate digestive symptoms suggestive of irritable bowel syndrome or screening for colorectal cancer. Exclusion Criteria: For all patients and control subjects * Subjects under guardianship, curatorship or safeguard of justice. * Subjects who do not speak French. IBD patients: \- Colon preparation within 6 weeks before stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards). Endoscopy control' and "microbiota control" subjects: * Subject suffering from a chronic disease * Antibiotics taken in the 6 weeks prior to endoscopy * Antibiotics or colonic preparation taken within 6 weeks prior to stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn IBD (inflammatory bowel disease) Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.